Search clinical trials for: BIRT 2584 XX

Total 501 results

Boehringer Ingelheim

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of BIRT 2584 XX Administered as Multiple Doses and Safety and Pharmacokinetics of BIRT 2584 XX Administered With and Without Food as Single Dose to Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Double-blind, Randomised, Placebo-controlled Trial Investigating BIRT 2584 XX in Patients With Moderate/Severe Psoriasis

Psoriasis

Germany, Denmark, Belgium, Canada, France, Sweden, Netherlands, Finland, Spain, United Kingdom
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of BIRT 2584 XX in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Study to Evaluate the Effect of Multiple Doses of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Midazolam in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Study to Evaluate the Effect Single and Multiple Oral Doses of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Amitriptyline and Nortriptyline in Healthy Male and Female Subjects

Healthy
Boehringer Ingelheim

Terminated

A Multiple Increasing Dose Safety and Tolerability Study After Inhalation Administration of BIIX 1 XX in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Preliminary Bioequivalence Study of UHAC 62 XX Tablets Compared With a Capsule Formulation in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence Study of UHAC62XX Tablets Compared With Capsules in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence Study of UHAC 62 XX Tablets Compared With Capsules in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence Study of UH-AC 62 XX Tablets Compared With the Capsule Formulations in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Study to Explore Pharmacokinetics and Pharmacodynamics of a Single Rising Dose of BI 135585 XX

Healthy

Germany
Boehringer Ingelheim

Completed

Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 163538 XX

Healthy

Germany
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 135585 XX in Health Asian Male Volunteers.

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Butylated Hydroxytoluene and BI 54903 XX Via Respimat® Soft MistTM Inhaler B in Healthy Male Volunteers

Healthy
Polaris Health Directions
University of Massachusetts, Worcester

Completed

Remote Brief Intervention and Referrals to Treatment Service for Alcohol (RBIRT)

Alcohol Abuse, Alcohol Dependence

United States
Biotronik SE & Co. KG
Biotronik, Inc.

Terminated

Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads (QP ExCELs)

Heart Failure

United States, Switzerland, Denmark, Israel, Hungary, Italy, Germany, Austria, Australia, Slovakia, Spain
CTI BioPharma

Terminated

CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy

Prostate Cancer

United States
Boehringer Ingelheim

Completed

Dose Extension Study of BIIX 1 XX in Healthy Young Male Volunteers

Healthy
Assistance Publique - Hôpitaux de Paris

Terminated

Study of Growth-promoting and Metabolic Effects of Growth Hormone (rhGH) (SGA)

Small for Gestational Age

France
Universidade Federal de Sao Carlos
Conselho Nacional de Desenvolvimento Científico e Tecnológico

Completed

Randomized Controlled Study to Investigate the Impact of Different Intensities Training on ADL and BODE Index in COPD

Chronic Obstructive Pulmonary Disease

Brazil
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacodynamics of BIIX 1 XX in Healthy Young Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Free Combination of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Relative Bioavailability, Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients

Cystic Fibrosis
Bristol-Myers Squibb

Completed

Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States
Treatment Research Institute
Pennsylvania Department of Health

Completed

Integrating Substance Abuse Assessment & Intervention in Primary Care Settings

Alcohol Use | Drug Use

United States
Boehringer Ingelheim

Completed

Efficacy and Safety of BIIL 284 BS in Adult Patients With Active Rheumatoid Arthritis

Arthritis, Rheumatoid
Spaulding Rehabilitation Hospital

Not yet recruiting

BurtVision™ for Arm Rehabilitation in Chronic Stroke Survivors:

Stroke
Ospedale Generale Di Zona Moriggia-Pelascini

Completed

Aquatic Therapy for Freezing of Gait in Parkinson's Disease Patients (AT-FOG)

Parkinson Disease | Gait Disorders, Neurologic | Gait Disorder, Sensorimotor

Italy
Ospedale Generale Di Zona Moriggia-Pelascini

Completed

Aquatic Therapy Versus Land-Based Therapy for the Treatment of Balance Dysfunction in Parkinson's Disease

Parkinson Disease

Italy
Ospedale Generale Di Zona Moriggia-Pelascini

Unknown

Effectiveness of Different Approaches for the Rehabilitation of Gait in Patients With Parkinson's Disease (Tr-T-VR)

Rehabilitation | PD | Gait Dysfunction, Neurologic

Italy
Boehringer Ingelheim

Completed

Effect of Treatment With BIIL 284 BS on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients

Cystic Fibrosis
Spaulding Rehabilitation Hospital
Barrett Technology

Not yet recruiting

PostureCheck: A Vision-based Compensatory-posture-detection Tool for Robot-assisted Upper-limb Therapy

Stroke
Novartis Pharmaceuticals
Chiron Corporation

Terminated

Safety of CHIR-258 (TKI258) in Advanced Solid Tumors

Neoplasms | Cancer | Tumors

United Kingdom
Andarix Pharmaceuticals

Recruiting

Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy

Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Carcinoma, Small Cell | Neoplasm Recurrence, Local

United States
University of Colorado, Denver
National Institute of Mental Health (NIMH); Washington State University; University...

Recruiting

Suicide in Urban Natives: Detection and Networks to Combat Events (SUNDANCE)

Suicide Prevention

United States
Boehringer Ingelheim

Completed

Relative Bioavailability, Safety and Tolerability of Two Tablet Formulations of BIIL 284 BS

Healthy
Shanghai Proton and Heavy Ion Center

Not yet recruiting

Individualized Carbon-Ion Radiotherapy for Patients With Locally Recurrent Nasopharyngeal Carcinoma

Locally Recurrent Nasopharyngeal Carcinoma

China
Boehringer Ingelheim

Completed

Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Patients With Hepatic Impairment in Comparison to Healthy Volunteers

Hepatic Insufficiency
Centre Hospitalier Universitaire de Besancon
Plateforme Neuraxess

Recruiting

Awareness of Emotional Feelings and Management of Risky Situations (COSMOS)

Emotional Regulation | Risk-Taking

France
Boehringer Ingelheim

Completed

The Effect of BIIL 284 BS on Induced-sputum Variables in Patients With Bronchial Asthma

Asthma
Boehringer Ingelheim

Completed

Effect of BIIL 284 BS on Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Atrogi AB
Key2Compliance; CRS Clinical Research Services

Completed

First-in-human Single and Multiple Dose Trial of ATR-258

Type 2 Diabetes Mellitus

Germany
M.D. Anderson Cancer Center
Novartis

Completed

TKI258 in Castrate Resistant Prostate Cancer

Prostate Cancer

United States
Pfizer

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza

Influenza, Human

United States
The University of Texas Health Science Center at...
National Institute on Aging (NIA)

Recruiting

Blood Flow Restriction Training in Individuals Awaiting Total Knee Replacement

Knee Osteoarthritis

United States
Amasya University
Ataturk University

Not yet recruiting

The Effect of Birth Ball and Birth Dance Applied in the First Stage of Labor on Some Parameters

Satisfaction, Patient | Pain, Labor
Boehringer Ingelheim

Completed

Metabolism and Pharmacokinetics of [14C]-BIIL 284 BS in Healthy Volunteers

Healthy

3

Subscribe